GlassScriptPhysician profile
Jason C Saylor
NPI 1407086846
$102,512.80
in general payments reported to CMS, 2019-2025
35 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,938 · 2020: $3,148 · 2021: $29K · 2022: $28K · 2023: $19K · 2024: $21K · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,750.39 |
| Food and Beverage | $1,607.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $95,639.54 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $884.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $869.47 | 2019-2025 | Farxiga |
| Supernus Pharmaceuticals, INC. | $551.47 | 2019-2023 | Qelbree, Xyosted |
| Abbvie INC. | $536.49 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $440.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $409.85 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $373.68 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.22 | 2019-2024 | Jardiance |
| Pfizer INC. | $268.68 | 2019-2025 | |
| Allergan, INC. | $264.32 | 2019-2020 | |
| Astellas Pharma US INC | $258.90 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $205.57 | 2019-2024 | |
| Amgen INC. | $182.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $163.74 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.86 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $122.63 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $120.45 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $114.43 | 2019-2022 | |
| Glaxosmithkline, LLC. | $90.04 | 2019-2024 | Trelegy Ellipta |
| Dexcom, INC. | $89.77 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $69.38 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $61.49 | 2023 | |
| Vivus LLC | $54.81 | 2019-2020 | |
| Exact Sciences Corporation | $53.01 | 2023-2025 | Cologuard Collection Kit |
| Tris Pharma INC | $37.09 | 2024 | Dyanavel Xr |
| Abbott Laboratories | $20.54 | 2021 | |
| Halozyme INC | $18.64 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.19 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $15.73 | 2025 | Injectafer |
| Ironshore Pharmaceuticals INC. | $13.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.47 | 2020 | |
| Medtronic USA, INC. | $11.32 | 2019 | |
| Boston Scientific Corporation | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Saylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.